Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9343MR)

This product GTTS-WQ9343MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9343MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ4891MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ13124MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ15555MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ9615MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ3388MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ8622MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ15332MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW